Intravenous Immunoglobulins: Mechanisms of Action and Possible Clinical Applications | CMAC

Intravenous Immunoglobulins: Mechanisms of Action and Possible Clinical Applications

Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):273-281

​ Avertchenkov V.M., Palagin I.S.
intravenous immunoglobulins mechanisms of action indications side effects
Section
Therapeutic Issues
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):273-281

Abstract

Historically, intravenous immunoglobulins (ivIg) were initially used as replacement therapy in patients with antibody deficiency disorders.Later on ivIg were suggested to have advantages in treatment of patients with autoimmune and systemic inflammatory diseases.Different mechanisms of ivIg activity have been proposed, such as neutralization of superantigens, inhibition of complement deposition, Fcγ receptor blockade, etc.The data on possible side effects of ivIg and its suggested mechanisms are also presented.

  • 1. Kazatchkine M., Kaveri S. Immunomodulation of autoimmune and inflammatory diseases witch intravenous immune globulin. N Engl J Med 2001; 345:747-55.
  • 2. Lam L., Whitsett C.F., McNicholl J.M., Hodge T.W., Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342:678.
  • 3. Kistler P., Nitschmann H. Large scale production of human plasma fractions. Vox Sang 1962; 7:414.
  • 4. Tankersley D., Preston M., Finlayson J. Immunoglobulin G dimer: an idiotypic-anti-idiotypic complex. Mol Immunol 1988; 22:41-8.
  • 5. Ravetch J. Fc receptors. Cell 1994; 78:553-60.
  • 6. Gavin A., Hulett M., Hogarth P. Molecular basis for the interaction of Fc receptors with immunoglobulins. In: van de Winkel J.G.J., Hogarth P.M., editors. The Immunoglobulin Receptors and Their Physiological and Pathological Roles in Immunity. Vol 26. The Netherlands: Kluwer Academical Publishers; 1998; р11-35.
  • 7. Looney R., Abraham G., Anderson C. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 1986; 136:1641-7.
  • 8. Ravetch J., Lanier L. Immune inhibitory receptors. Science 2000; 290:84-9.
  • 9. Daeron M. Negative regulation of mast cell activation by receptors for IgG. Int Arch Allergy Immunol 1997; 113:138-41.
  • 10. Edberg J., Redecha P., Salom J., Kimberly R. Human FcγRIII (CD16): Isoforms with distinct allelic expression, extracellular domains and membrane linkages on polymorphonuclear and natural killer cells. J Immunol 1989; 143:1642-9.
  • 11. Simmons D., Seed B. The Fcγ receptor of natural killer cells is a phospholipid-linked membrane protein. Nature 1988; 333:568-570.
  • 12. Selvaraj P., Rosse W., Silber R., Pringer T. The major Fcγ receptor in blood has a phosphatidylinositol anchor and its deficiency in paroxysmal nocturnal heamoglobinuria. Nature 1988; 333:565-7.
  • 13. Ravetch J., Kinet J. Fc receptors. Ann Rev Immunol 1991; 9:457-92.
  • 14. Young J., Ko S., Cohn A. The increase in intracellular free calcium associated with IgGγ2b/γ1 Fc receptor-ligand interaction: role in phagocytosis. Proc Natl Acad Sci USA 1984; 81:5430.
  • 15. Imbach P., Barandun S., d’Apuzzo V. High dose intravenous gammaglobulin for idiotypic trombocytopenia purpura in childhood. Lancet 1981; 1:1228-31.
  • 16. Fridmann W. Regulation of B-cell activation and antigen presentation by Fc receptors. Curr Opin Immunol 1993; 5:355-60.
  • 17. Yu Z., Lennon V. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227-8.
  • 18. Bleeker W., Teeling J., Hack C. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001; 98:3136-42.
  • 19. Basta M., Kirhsbom P., Frank M., Fries L. Mechanisms of therapeutic effect of high dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84:1974-81.
  • 20. Mollnes T., Hogasen K., Hoaas B., Michaelsen T., Garred P., Harboe M. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the Ig isotype and its C1 binding properties. Scand J Immunol 1995; 41:449-56.
  • 21. Ruiz P., Gomez G., Lopez R., Chien P., Rossman M., Schreiber A. Granulocyte Fcγ receptor recognition of cell bound and aggregated IgG: effect of γinterferon. Am J Hematol 1992; 39:257-63.
  • 22. Leung D., Burns J., Newburger J., Geha R. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987; 79:468-72.
  • 23. Andersson U., Bjork L., Skansen-Saphir U., Andersson J. Down-regulation of cytokine production and IL-2 receptor expression by pooled human IgG. Immunology 1993; 79:211-6.
  • 24. Aukrust P., Froland S., Liabakk N., et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84:2136-42.
  • 25. Anderson U., Bjork L., Skansen-Saphir U., Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994; 139:21-42.
  • 26. Kekow J., Reinhold D., Pap T., Ansorge S. Intravenous immunoglobulins and transforming growth factor β. Lancet 1998; 351:184-5.
  • 27. Rossi F., Jayne D., Lockwood C., Kazatchine M. Antiidiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991; 83:298-303.
  • 28. Tankersley D.L. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immunоglobulin in autoimmune disease. Immunol Rev 1994; 139:159-72.
  • 29. Kazatchine M., Dietrich G., Hurez. V. Region-mediated selection of autoreactive repertoires by intravenous immunoglobulin. Immunol Rev 1994; 139:79-107.
  • 30. Jayne D., Davies M., Fox C., Lockwood C. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337:1137-9.
  • 31. Delfraissy J., Tchernia G., Laurian Y., Wallon C., Galanaud P. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol 1985; 60:315-22.
  • 32. Kondo N., Ozawa T., Mushiake K., et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991; 11:152-8.
  • 33. Diegel M., Rankin B., Bolen J., Dupuis P., Kiener P. Cross linking of Fc receptor to surface immunoglobulin on E cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem 1994; 269:11409-16.
  • 34. Vassilev T., Gelin C., Kaveri S., Xilber M., Boumsell L., Kazatchine M. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993; 92:369-72.
  • 35. Prasad N., Papoff G., Zeuner A., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas Apoptotic pathway. J Immunol 1998; 161:3781-90.
  • 36. Dalakas M. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med 1997; 126:721-30.
  • 37. Marchalonis J., Kaymaz H., Dedeoglu F., Schluter S., Yocum D., Edmunson A. Human autoantibodies reactive with synthetic autoantigens from T’ cell receptor 20 chain. Proc Natl Acad Sci USA 1992; 89:3325-9.
  • 38. Takei S., Arora Y., Walker S. Intravenous immunoglobulin contains specific antibodies inhibitory of activation of T cells by staphyloccocal toxin superantigens. J Clin Invest 1993; 91:602-7.
  • 39. Glotz D., Haymann J., Niaudet P., Lang P., Druet P., Bariety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transpl Proc 1995; 27:1038-9.
  • 40. Duhem C., Dicato M., Ries F. Side effects of intravenous immunоglobulins. Clin Exp Immunol 1994; 97(Suppl I): 79-83.
  • 41. Ryan M., Webster M., Statler J. Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr 1996; 35:23-31.
  • 42. Strangel M., Hartung H., Marx P., Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol 1997; 20:385-93.
  • 43. Hachimi-Idrissi S., de Scheffer J., Dab I., Otten J. Type III allergic reaction after infusion of immunoglobulins. Lancet 1990; 336:55.
  • 44. Teeling J., Bleeker W., Rigter G., van Rooijen N., Kuijpers T., Hack C. Intravenous immunoglobulin preparations induce mild activation of neutrophils in vivo via triggering of macrophages. Studies in a rat model. Br J Haematol 2001; 112:1031-41.
  • 45. Alving B., Tankersley D., Mason B., Rossi F., Aronson D., Finlayson J. Contact-activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive properties. J Lab Clin Med 1980; 96:334-46.
  • 46. Bagdasarian A., Tonetta S., Harel W., Mamidi W., Uemura Y. IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang 1998; 74:74-82.
  • 47. Burks A., Sampson H., Buckley R. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986; 314:560-3.
  • 48. Kobosko J., Nicol F. Renal toxicity of intravenous immunoglobulin. Clin Nephrol 1993; 37:216-7.
  • 49. Teeling J., Bleeker W., Hack C. History, biological mechanisms of action and clinical indication of intravenous immunoglobulin preparation. Rev Med Microbiol 2002; 13:91-100.
  • 50. Костинов М.П. Иммунокоррекция в педиатрии. М: Медицина для всех; 2001. 240 с.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared